KR20210003197A - 폐 질환 치료에 사용하기 위한 흡입 가능한 리포솜 서방형 조성물 - Google Patents

폐 질환 치료에 사용하기 위한 흡입 가능한 리포솜 서방형 조성물 Download PDF

Info

Publication number
KR20210003197A
KR20210003197A KR1020207033553A KR20207033553A KR20210003197A KR 20210003197 A KR20210003197 A KR 20210003197A KR 1020207033553 A KR1020207033553 A KR 1020207033553A KR 20207033553 A KR20207033553 A KR 20207033553A KR 20210003197 A KR20210003197 A KR 20210003197A
Authority
KR
South Korea
Prior art keywords
liposome
mol
drug
composition
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207033553A
Other languages
English (en)
Korean (ko)
Inventor
키룽 홍
조나단 팡
유-쳉 쳉
팅-유 쳉
완-니 유
조-신 탕
Original Assignee
티엘씨 바이오파머슈티컬즈 인코포레이티드
타이완 리포솜 캄퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티엘씨 바이오파머슈티컬즈 인코포레이티드, 타이완 리포솜 캄퍼니 리미티드 filed Critical 티엘씨 바이오파머슈티컬즈 인코포레이티드
Publication of KR20210003197A publication Critical patent/KR20210003197A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207033553A 2018-04-23 2019-04-23 폐 질환 치료에 사용하기 위한 흡입 가능한 리포솜 서방형 조성물 Ceased KR20210003197A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661217P 2018-04-23 2018-04-23
US62/661,217 2018-04-23
PCT/US2019/028647 WO2019209787A1 (en) 2018-04-23 2019-04-23 Inhalable liposomal sustained release composition for use in treating pulmonary diseases

Publications (1)

Publication Number Publication Date
KR20210003197A true KR20210003197A (ko) 2021-01-11

Family

ID=66821301

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207033553A Ceased KR20210003197A (ko) 2018-04-23 2019-04-23 폐 질환 치료에 사용하기 위한 흡입 가능한 리포솜 서방형 조성물

Country Status (12)

Country Link
US (2) US11534399B2 (https=)
EP (1) EP3784213B1 (https=)
JP (1) JP7391039B2 (https=)
KR (1) KR20210003197A (https=)
CN (1) CN112004527B (https=)
AU (1) AU2019261329B2 (https=)
BR (1) BR112020021412A8 (https=)
CA (1) CA3101102A1 (https=)
ES (1) ES2964413T3 (https=)
IL (1) IL278079B2 (https=)
TW (1) TWI866908B (https=)
WO (1) WO2019209787A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023022520A1 (ko) * 2021-08-18 2023-02-23 주식회사 삼양홀딩스 룩소리티닙의 경구용 정제 조성물 및 이의 제조 방법

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004527B (zh) 2018-04-23 2024-09-24 盈擘生技股份有限公司 用于治疗肺部疾病的可吸入脂质体缓释组合物
WO2020055713A1 (en) * 2018-09-10 2020-03-19 Taiwan Liposome Co., Ltd. Sustained-release ophthalmic pharmaceutical compositions and uses thereof
US12599557B2 (en) 2019-04-25 2026-04-14 Tlc Biopharmaceuticals, Inc. Liposomal sustained-release compositions containing a therapeutic drug and use thereof
CN114040750B (zh) * 2019-05-14 2025-11-11 盈擘生技股份有限公司 用于治疗肺部疾病的可吸入支气管扩张剂缓释组合物
TW202143949A (zh) * 2020-03-22 2021-12-01 盈擘醫藥股份有限公司 用於預防或暴露後治療感染或呼吸疾病的抗病毒組成物
CN112472791A (zh) * 2020-11-16 2021-03-12 复旦大学 CsA脂质体在制备抗SARS-CoV-2药物中的应用
CN116635009A (zh) * 2020-12-14 2023-08-22 纳米科技制药公司 用于递送抗癌剂的具有改进的治疗指数的组合物和方法
CN114642656B8 (zh) * 2020-12-18 2025-12-12 盈科瑞（天津）创新医药研究有限公司 一种吸入用尼达尼布溶液及其制备方法
KR102348901B1 (ko) * 2021-08-26 2022-01-07 충북대학교 산학협력단 레고라페닙을 유효성분으로 포함하는 만성폐쇄성 폐질환의 예방 또는 치료용 조성물
CN116064394A (zh) * 2021-11-01 2023-05-05 中国医学科学院医药生物技术研究所 肿瘤细胞外泌体与脂质体的杂化外泌体、其制备方法及其抗肿瘤用途
JP2025069482A (ja) * 2022-03-25 2025-05-01 国立研究開発法人医薬基盤・健康・栄養研究所 特発性肺線維症の治療または予防剤
TW202415382A (zh) * 2022-09-30 2024-04-16 大陸商上海濟煜醫藥科技有限公司 脂質體藥物組合物及其製備方法和用途
BE1031669B1 (fr) * 2023-06-02 2025-01-14 Inhatarget Therapeutics Composition pharmaceutique pour inhalation
EP4637764A1 (en) * 2023-12-22 2025-10-29 Zedira GmbH Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis
WO2025138298A1 (zh) * 2023-12-30 2025-07-03 北京睿创康泰医药研究院有限公司 一种尼达尼布超分子复合体的药物组合物
CN117899020A (zh) * 2024-01-16 2024-04-19 中山大学 一种载抗生素黏液渗透型脂质体粉雾剂的制备方法及其应用
CN118948812A (zh) * 2024-08-06 2024-11-15 北京悦康科创医药科技股份有限公司 一种多肽脂质体吸入剂及其制备方法和应用
KR102859152B1 (ko) * 2024-10-24 2025-09-12 주식회사 한국리포좀 합성 지질 리포좀 기반의 일본 뇌염 바이러스 백신 및 그의 제조방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686025T2 (de) 1985-05-22 1993-01-07 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
IE63869B1 (en) 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
US5958378A (en) 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
GB9912639D0 (en) 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
DE10214983A1 (de) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
EP1581236B1 (en) 2002-10-29 2013-10-16 Insmed Incorporated Sustained release of antiinfectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
KR20060015265A (ko) * 2003-05-30 2006-02-16 알자 코포레이션 제제의 폐 투여 방법
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
US8071127B2 (en) 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
JP2010540498A (ja) * 2007-09-28 2010-12-24 ウニヴェルズィテーツシュピタール バーゼル 癌の治療のための免疫リポソーム
WO2012027727A2 (en) * 2010-08-26 2012-03-01 Kunyuan Cui Lipomacrocycles and uses thereof
WO2012031603A2 (en) 2010-09-09 2012-03-15 Danish Medical Consults Aps Airway administration of angiogenesis inhibitors
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
EP4309657A3 (en) * 2013-02-01 2024-02-28 Celator Pharmaceuticals, Inc. Remote loading of sparingly water-soluble drugs into liposomes
JP6799201B2 (ja) * 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
KR20150026613A (ko) * 2013-09-03 2015-03-11 삼성전자주식회사 소수성 물질 및 조영제를 포함하는 리포좀 및 그의 용도
NZ760541A (en) 2014-01-10 2022-08-26 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2016090111A1 (en) 2014-12-05 2016-06-09 Vindico NanoBio Technology Inc. Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
US20180344644A1 (en) * 2015-09-21 2018-12-06 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
CN108601746B (zh) * 2016-01-08 2024-09-13 加利福尼亚大学董事会 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒
CA3013768A1 (en) * 2016-02-04 2017-08-10 Stem Cell Theranostics, Inc. Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
CN112004527B (zh) 2018-04-23 2024-09-24 盈擘生技股份有限公司 用于治疗肺部疾病的可吸入脂质体缓释组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023022520A1 (ko) * 2021-08-18 2023-02-23 주식회사 삼양홀딩스 룩소리티닙의 경구용 정제 조성물 및 이의 제조 방법

Also Published As

Publication number Publication date
TW202011941A (zh) 2020-04-01
CA3101102A1 (en) 2019-10-31
JP2021522163A (ja) 2021-08-30
ES2964413T3 (es) 2024-04-05
WO2019209787A1 (en) 2019-10-31
IL278079B2 (en) 2025-08-01
BR112020021412A2 (pt) 2021-01-19
TWI866908B (zh) 2024-12-21
BR112020021412A8 (pt) 2022-07-05
US20230088661A1 (en) 2023-03-23
US11534399B2 (en) 2022-12-27
IL278079A (en) 2020-11-30
EP3784213B1 (en) 2023-09-06
CN112004527B (zh) 2024-09-24
US12533313B2 (en) 2026-01-27
EP3784213A1 (en) 2021-03-03
IL278079B1 (en) 2025-04-01
EP3784213C0 (en) 2023-09-06
CN112004527A (zh) 2020-11-27
JP7391039B2 (ja) 2023-12-04
AU2019261329A1 (en) 2020-11-12
US20210145740A1 (en) 2021-05-20
AU2019261329B2 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
US12533313B2 (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases
JP4885715B2 (ja) イリノテカン製剤
US20080026049A1 (en) Liposomal compositions for parenteral delivery of agents
CN116635009A (zh) 用于递送抗癌剂的具有改进的治疗指数的组合物和方法
JP2014506918A (ja) 抗腫瘍活性物質を含むリポソーム製剤、その調製のための方法、及び、それを含む医薬組成物
US20260108534A1 (en) Liposomal formulations of bcl inhibitors
WO2010095964A1 (en) A method for amphiphilic drug loading in liposomes by ion gradient
US20220211623A1 (en) Inhalable sustained release composition of bronchodilator for use in treating pulmonary disease
HK40043569A (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases
HK40043569B (zh) 用於治疗肺部疾病的可吸入脂质体缓释组合物
JP2024526800A (ja) Ｂｃｌ阻害剤のリポソーム製剤
HK40054349A (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof
CN113056259A (zh) 包含用于治疗因骨密度降低或软骨损失导致的疾病的治疗剂的缓释药物组合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000